{
    "Trade/Device Name(s)": [
        "LZI Cotinine II Enzyme Immunoassay"
    ],
    "Submitter Information": "Lin-Zhi International, Inc.",
    "510(k) Number": "k192299",
    "Predicate Device Reference 510(k) Number(s)": [
        "k963733"
    ],
    "Regulatory Class": "Class I, reserved",
    "Product Code(s)": [
        "MKU"
    ],
    "Summary Letter Date": "August 19, 2019",
    "Summary Letter Received Date": "August 23, 2019",
    "Submission Date": "August 21, 2019",
    "Regulation Number(s)": [
        "21 CFR 862.3220"
    ],
    "Regulation Name(s)": [
        "Carbon monoxide test system"
    ],
    "Analyte Class(es)": [
        "toxicology"
    ],
    "Analyte(s)": [
        "Cotinine"
    ],
    "Specimen Type(s)": [
        "Urine"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Beckman Coulter AU480 automated clinical analyzer",
        "Automated clinical chemistry analyzers"
    ],
    "Method(s)/Technology(ies)": [
        "Homogeneous enzyme immunoassay",
        "Spectrophotometric measurement"
    ],
    "Methodologies": [
        "Enzyme immunoassay"
    ],
    "Submission Type(s)": [
        "Kit",
        "Reagent"
    ],
    "Document Summary": "FDA 510(k) summary for LZI Cotinine II Enzyme Immunoassay for qualitative and semi-quantitative detection of cotinine in human urine using automated clinical chemistry analyzers.",
    "Indications for Use Summary": "Intended for qualitative and semi-quantitative determination of cotinine in human urine as an aid in detecting use or exposure to tobacco products; designed for prescription use with automated clinical chemistry analyzers.",
    "fda_folder": "Toxicology"
}